title: Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
authors.forename: Maria
authors.initials: M
authors.lastname: Sironi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Bertola
authors.forename: Antonio
authors.initials: A
authors.lastname: Lodato
authors.forename: Maurizio
authors.initials: M
authors.lastname: Spinelli
authors.forename: Luca
authors.initials: L
authors.lastname: Sciariada
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects*; D007947:Leukemia, Megakaryoblastic, Acute / Q000209:etiology* / Q000473:pathology; D008297:Male; D008533:Megakaryocytes / Q000473:pathology; D008875:Middle Aged; D010885:Pipobroman / Q000008:administration & dosage / Q000009:adverse effects*; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D010885:Pipobroman; D002066:Busulfan; D006918:Hydroxyurea